期刊文献+

糖尿病肾病大鼠肝DNA甲基化酶活性及基因组DNA对DNase敏感性的分析 被引量:2

ACTIVITY OF DNA METHYLASE AND DNASE SENSITIVITY ASSAY OF GENOME DNA OF LIVER FROM RAT OF DIABETIC NEPHROPATHY
下载PDF
导出
摘要 用 3H标记的 S-腺苷酰 - L -甲硫氨酸 (3H- SAM)作为甲基供体 ,以同位素掺入法测定了正常大鼠、糖尿病肾病大鼠、中药“糖微康”治疗的糖尿病肾病大鼠、西药“开博通”治疗的糖尿病肾病大鼠的肝细胞的 DNA甲基化酶活性 ,并对从以上各组动物肝组织中提取的基因组 DNA分别进行 DNase 敏感性分析 .结果显示 :糖尿病肾病大鼠肝 DNA甲基化酶活性明显低于正常鼠肝 ,其基因组 DNA对 DNase 敏感性比正常大鼠肝增强 ;中药“糖微康”治疗及西药“开博通”治疗的大鼠的肝 DNA甲基化酶活性均有所回升 ,且中药组更接近正常大鼠对 DNase 的敏感性 . The activity of DNA metlylase is measured from control animals,animals of Diabetic Nephropathy, animals of Diabetic Nephropathy treated with Chinese traditional medicine 'Tang Wei Kang', and animals of Diabetic Nephropathy treated with medicine Capton by measuring incorperation of 3H-methyl. 3H-S-adenosyl-L-methionine ( 3H-SAM) is used as methyl donor. At the same time, the sensitivity of DNA from different rat liver to DNase Ⅰ is mersured. The results demonstrate that DNA methylase activity of rat liver of Diabetic Nephropathy is obviously lower than the control, and its genome DNA possesses higher sensitivity to Dnase I than that of the control. However, DNA methylase activity of rat liver of Diabetic Nephropathy treated with Chinese traditional medicine 'Tang Wei Kang' or the medicine Capton is all reversed to the control level. Meanwhile, the sensitivity of the former's DNA to DNase I is closely to the control.
出处 《北京师范大学学报(自然科学版)》 CAS CSCD 北大核心 2002年第6期810-814,共5页 Journal of Beijing Normal University(Natural Science)
基金 "九五"国家科技攻关资助项目 (96 - 90 6 - 0 9- 0 7)
关键词 大鼠 酶活性 基因组DNA 敏感性 糖尿病肾病 DNA甲基化酶 DNaseⅠ 糖微康 中药 药理机制 Diabetic Nephropathy DNA methylase DNase Ⅰ Tang Wei Kang (Chinese traditional medcine)
  • 相关文献

参考文献3

二级参考文献6

共引文献24

同被引文献15

  • 1杨俊伟,黎磊石,张真.大黄治疗糖尿病肾病的实验研究[J].中华内分泌代谢杂志,1993,9(4):222-224. 被引量:105
  • 2Ihrn CG. Monocyte chemotatic peptide-1 in diabetic nephropathy[J]. Kidney Int, 1997,52(suppl): 20-22.
  • 3Wenzel UO. Chemokines and renal disease[J]. Am J Kidney Dis, 1995,26:982-995.
  • 4Dubois,Nochy D,Chanson P,et al. Remission of proteinuria following correction of hyperfipidemia in NIDDM Patients with nondiabetic glomerulopathy. Diabetes Care,1994,17 : 906.
  • 5Meryer I J, Szukies B, Neubauer K, et al. Extracellular matrix proteins as a early markers in diabetic nephropathy.Eur J Clin Chem Clin Biochem, 1995,33: 211 -214.
  • 6Ching-Ye Hong,Kenneth Hughes,Kee-Seng Chia,et al.Urinary α1-Microglobulin as a Marker of Nephropathy in Type 2 Diabetic Asian Subjects in Singapore.Diabetes Care,2003,26:338-342.
  • 7Verhulst A,Persy VP,Van Rompay AR,et al.Osteopontin synthesis and localization along the Human Nephron.J Am Soc Nephrol,2002,(13):1210-1218.
  • 8Okada H,Moriwaki K,Kalluri R,et al.Osteopontin expressed by renal tubular epithelium mediates interstitial monocyte infiltration in rats.J Am Physiol Renal Physiol,2000,278:110-121.
  • 9Chow F,Ozols E,Nikolic-Paterson DJ,et al.Macrophages in mouse type 2 diabetic nephropathy:Correlation with diabetic state and progressive renal injury.Kidney Int,2004,65(1):116-128.
  • 10Morcos M,sayed AA,Bierhaus A,et al.Activation of tubular epithelial cells in diabetic nephropathy.J Diabetes,2002,51:3532-3544.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部